RESEARCH EXPLAINED: SS-31 is one of the few "mitochondria peptides" with an FDA approval, but the approval is narrow, conditional, and built on a mixed set of trials. No big new peptide study or regulatory decision came out in the last 48 hours that we haven't already covered, so today we're breaking down a compound that comes up a lot in mitochondria conversations and hasn't been covered here yet. WHAT IT IS Elamipretide, first developed under the name SS-31, is a small peptide made by Stealth BioTherapeutics. On September 19, 2025, the FDA gave it accelerated approval under the brand name Forzinity. It was the first therapy approved for Barth syndrome and the first FDA-approved drug designed to target mitochondria. (1)(2) Barth syndrome is an ultra-rare genetic disease. The company estimates about 150 people in the U.S. have it, and it occurs in roughly 1 in 1,000,000 male births. (2) The approval covers only one use: improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. (2)(3) WHAT THEY FOUND TAZPOWER (Barth syndrome). In the randomized, placebo-controlled part of this trial, people took elamipretide for 12 weeks and placebo for 12 weeks in random order. That part did not meet its primary or secondary goals. (4) In the open-label extension, where everyone knew they were on the drug, 8 of 10 participants reached week 168. Six-minute walk distance improved by a combined 96.1 meters by week 168, and fatigue scores and heart measurements also improved. (3)(4) The FDA path. The FDA turned the drug down in May 2025 because it missed a six-minute walk goal. The company resubmitted using knee extensor (thigh) muscle strength, which the FDA treated as an "intermediate" marker likely to predict real benefit, like standing up or walking more easily. (1) MMPOWER-3 (a different disease). In a 24-week Phase 3 trial of 218 adults with primary mitochondrial myopathy, elamipretide at the dose studied in this trial (40 mg daily) did no better than placebo overall. The six-minute walk difference was -3.2 meters, and fatigue scores were also no different. A subgroup with nuclear DNA mutations walked about 25 meters farther than placebo, which the researchers called hypothesis-generating, not proof. (5)